News

NEAT1 (Nuclear Enriched Abundant Transcript 1), a long non-coding RNA molecule, might be protecting neurons in Huntington’s disease (HD) a new study suggests.

During the 68th American Academy of Neurology (AAN) meeting in Vancouver, Teva Pharmaceutical Industries Ltd. presented new results from its Phase III First-HD clinical trial evaluating the efficacy, safety and tolerability of SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington’s disease (HD), a…

A collaboration between researchers at the University of Leicester, U.K., and the University of Maryland School of Medicine, Baltimore, may lead to a way of reversing some symptoms of neurogedenerative diseases, like Huntington’s, by blocking two specific enzymes of the kynurenine pathway. The findings, published in the Proceedings of the…

A protein, known for its role in the kidneys, has been identified by University of Louisville scientists as a key player in axonal branching –  a process by which nerve cells extend  processes to connect to other nerve cells. The discovery of the protein’s crucial role will shed light…

Scientists at the University of Guelph in Canada, have concluded in a recent study, that exercise can increase the use of the neurotransmitter glutamate in the brain, potentially lowering toxicity associated with excessive levels of the compound in neurodegenerative conditions such as Huntington’s disease. Glutamate is one of the…

A professor at Washington University in St. Louis, Missouri, has been awarded two grants from the National Institutes of Health (NIH) totaling over $4.5 million to study Huntington’s disease (HD) and the causes behind this devastating disease. The recipient of the grants is Rohit V. Pappu, the Edwin H. Murty Professor…

Converging evidence suggests that neurodegenerative conditions, such as Huntington’s disease, are caused by persistent inflammatory immune processes that ultimately kill neurons. This insight, presented by researchers at University of Adelaide, Australia, might change the way researchers approach drug development for neurodegenerative diseases and possibly alter the trajectory of unsuccessful…

Over the last few decades, there has been an increasing number of clinical trials focused on the search of new therapeutic strategies to manage Huntington’s Disease (HD), an incurable neurodegenerative disease characterized by motor, cognitive and psychiatric problems. However, there have been few advances, and research is now focusing on…

Beneficial effects of the investigational neuroprotective drug olesoxime have mainly been attributed to its effects on mitochondria, but new research suggests it also blocks calpain — a molecule directly involved in Huntington’s disease. The findings indicate that exploring the drug’s exact mechanism might bring scientists closer to effective treatments for Huntington’s.

Olesoxime, a drug shown to have neuroprotective properties, may have beneficial effects in Huntington’s patients through reduction of calpain-mediated huntingtin cleavage, according to the study “The calpain-suppressing effects of olesoxime in Huntington’s disease,” published in the journal Rare Diseases. Olesoxime is a small molecule…